respiratori
infect
repres
lead
caus
acut
hospit
admiss
often
lead
seriou
complic
patient
chronic
immunomodulatori
condit
gener
popul
pediatr
elderli
patient
particularli
risk
infect
complic
histor
cultur
detect
direct
fluoresc
antibodi
stain
elisa
tradit
method
diagnosi
respiratori
infect
cultur
mani
organ
notori
insensit
due
fastidi
growth
requir
dfa
elisa
insensit
due
infect
fall
practic
sensit
methodolog
dfa
also
subject
technic
error
subjectiveinconsist
result
interpret
methodolog
also
shown
less
sensit
polymeras
chain
reaction
pcr
detect
method
viral
respiratori
pathogen
addit
influenza
b
rsv
rapidli
test
use
chromatograph
immunoaasay
ambulatori
care
set
howev
influenza
assay
particular
display
unaccept
sensit
taken
togeth
variou
limit
lead
delay
lack
pathogen
identif
well
inappropri
use
antimicrobi
therapi
molecular
platform
capabl
detect
respiratori
pathogen
current
avail
clear
fda
pcr
assay
unfortun
technolog
typic
requir
advanc
molecular
expertis
often
target
one
pathogen
assay
farp
idaho
technolog
inc
allow
simultan
detect
respiratori
pathogen
singl
pouch
format
technolog
combin
extract
purif
nucleic
acid
nest
pcr
autom
report
singl
pouch
close
assay
format
limit
time
drastic
reduc
chanc
contamin
assay
provid
routin
microbiolog
laboratori
tool
perform
molecular
detect
respiratori
pathogen
function
typic
limit
refer
laboratori
larg
hospit
system
comparison
studi
serv
independ
evalu
laboratori
interest
farp
candid
replac
viral
dfa
stain
studi
aim
evalu
select
analyt
farp
use
clinic
laboratori
use
nasopharyng
sampl
exclus
pediatr
popul
studi
investig
perform
analyt
adenoviru
adeno
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
influenza
flua
influenza
pandem
flua
influenza
b
flub
rhinoviru
rhino
parainfluenza
parainfluenza
parainfluenza
bordetella
pertussi
bpert
use
approv
version
assay
also
includ
bocaviru
goal
evalu
assay
perform
candid
replac
tradit
laboratori
techniqu
employ
mani
potenti
user
farp
nasopharyng
aspir
transport
media
previous
test
dfa
primari
children
medic
center
salt
lake
citi
ut
dfa
rvp
specif
rhinoviru
intermountain
central
laboratori
murray
ut
analyz
valid
studi
accord
institut
review
board
fda
approv
specimen
type
farp
nasopharyng
swab
util
institut
pediatr
specimen
obtain
children
age
year
clinic
specimen
initi
test
dfa
neg
specimen
reflex
rvp
test
thirti
posit
neg
clinic
sampl
select
test
obtain
minimum
posit
sampl
analyt
limit
clinic
isol
subset
cultur
organ
spike
previous
frozen
clinic
nasopharyng
specimen
screen
fluoresc
antibodi
initi
cultur
viral
infect
cell
use
spike
use
approxim
densiti
seen
clinic
posit
dfa
total
posit
neg
specimen
test
specif
breakdown
sampl
test
list
tabl
primari
patient
specimen
frozen
year
howev
four
fresh
specimen
includ
studi
day
dfa
test
flua
specimen
chosen
distribut
three
consecut
flu
season
platform
respiratori
panel
use
studi
ident
platform
evalu
fda
submiss
softwar
approv
system
report
result
analyt
test
wherea
fda
approv
panel
releas
result
analyt
except
bocaviru
machin
analyz
one
pouch
time
order
maxim
effici
minim
cost
analyt
pool
group
five
uniqu
analyt
per
run
pool
sampl
inject
farp
pouch
analysi
extract
amplif
detect
analysi
complet
autom
within
pouch
result
assay
provid
softwar
qualiti
control
reaction
appropri
detect
pouch
includ
intern
run
control
primari
amplif
analyt
specif
amplif
stage
set
perform
biosafeti
cabinet
discrep
result
resolv
cultur
fluoresc
antibodi
stain
andor
ldt
farp
result
exclud
rhino
cultur
posit
result
consid
discrep
analysi
neg
cultur
subsequ
interrog
ldt
schemat
algorithm
discrep
resolut
shown
figur
ldt
assay
perform
associ
region
univers
pathologist
arup
laboratori
salt
lake
citi
ut
ldt
flua
flub
rsv
perform
multiplex
assay
remain
analyt
perform
singleplex
reaction
nucleic
acid
ldt
obtain
extract
qiagen
biorobot
per
establish
procedur
resolut
achiev
cultur
fluoresc
antibodi
stain
andor
pcr
result
correl
either
initi
dfarvp
result
farp
result
clinic
sampl
cohort
analyt
quantifi
arup
laboratori
use
standard
curv
gener
log
dilut
plasmid
genom
dna
bpert
adeno
group
c
rna
transcript
rna
virus
serial
dilut
quantifi
clinic
sampl
prepar
media
pool
group
four
analyt
determin
limit
detect
lod
specimen
refriger
less
day
test
ldt
lod
determin
theoret
concentr
copiesml
calcul
dilut
analyt
test
four
time
singl
day
three
concentr
lod
lod
sampl
run
four
time
day
analyt
specif
assay
determin
spike
cultur
organ
transport
media
run
sampl
absenc
analyt
target
farp
posit
neg
percent
agreement
analyt
establish
farp
tabl
agreement
versu
current
laboratori
method
dfa
rvp
rhinoviru
desir
purpos
effect
replac
dfa
method
sever
analyt
agreement
initi
phase
valid
includ
bpert
flua
hmpv
remain
analyt
requir
investig
cultur
fluoresc
antibodi
andor
ldt
resolv
discrep
result
sever
sampl
resolv
cultur
fluoresc
antibodi
stain
requir
pcr
analysi
howev
specimen
store
freezer
neg
cultur
could
consid
absolut
resolut
sampl
resolv
ldt
interrog
reanalysi
discrep
sampl
flub
resolv
complet
agreement
two
method
tabl
remain
analyt
adeno
flua
attain
greater
posit
neg
agreement
versu
dfa
tabl
posit
percent
agreement
adeno
fell
pool
specimen
intend
contain
five
analyt
howev
seven
analyt
detect
sever
pool
pool
individu
specimen
interrog
individu
farp
confirm
identif
sampl
also
confirm
ldt
determin
fact
seven
distinct
analyt
present
two
deem
unexpect
posit
sever
analyt
detect
part
evalu
therefor
resolv
bocaviru
n
coronaviru
n
parainfluenza
n
chlamydophila
pneumonia
n
lod
analyt
determin
farp
use
ldt
lod
sampl
quantifi
pcr
analyt
concentr
determin
tabl
dilut
seri
also
test
ldt
compar
lod
ldt
farp
ldt
lod
valu
consist
lower
farp
except
rsv
ldt
lod
rsv
exceed
valu
origin
establish
assay
greater
log
sequenc
target
region
test
viru
perform
check
polymorph
potenti
affect
pcr
effici
sequenc
reveal
two
previous
undescrib
polymorph
like
account
differ
result
consist
ldt
farp
compar
low
lod
rsv
strain
contain
polymorph
two
analyt
compar
high
lod
valu
farp
adeno
bpert
interrog
individu
determin
whether
pool
analyt
neg
effect
lod
valu
neither
analyt
show
chang
lod
valu
assay
individu
farp
farp
perform
well
reproduc
studi
analyt
detect
consist
lod
three
time
lod
would
expect
analyt
show
vari
perform
sampl
dilut
lod
lod
determin
studi
also
provid
addit
reproduc
data
sinc
sampl
detect
triplic
singl
day
establish
lod
challeng
analyt
specif
farp
cultur
organ
spike
media
interrog
farp
organ
chosen
base
potenti
encount
nasopharyx
none
test
organ
cross
react
farp
includ
candida
albican
streptococcu
pneumonia
streptococcu
pyogen
haemophilu
influenza
type
b
staphylococcu
aureu
methicillin
resist
moraxella
catarrhali
aspergillu
sp
bordetella
bronchiseptica
respiratori
pathogen
current
achiev
dfa
mani
laboratori
howev
neither
rapid
sensit
mani
suspect
pathogen
result
industri
effort
toward
develop
rapid
sensit
molecular
diagnost
respiratori
pathogen
aggress
pursu
recent
year
mani
commerci
avail
one
assay
luminextm
xtag
rvp
shown
cost
effect
option
respiratori
pathogen
detect
use
result
shorter
hospit
stay
overal
canadian
hospit
technolog
howev
requir
profici
molecular
techniqu
well
dedic
amplicon
room
laboratori
unabl
practic
adopt
complex
multiplex
assay
interest
replac
viral
dfa
molecular
multiplex
test
farp
attract
altern
major
advantag
system
fulli
enclos
platform
overal
simplic
setup
perform
separ
molecular
work
area
molecular
expertis
requir
result
attribut
sever
recent
studi
compar
farp
pcr
platform
overal
agreement
one
studi
perform
clinic
comparison
immunocompromis
patient
howev
studi
provid
fulli
resolv
comparison
dfa
methodolog
like
displac
farp
clinic
laboratori
adopt
technolog
farp
perform
well
overal
comparison
studi
paramet
test
fact
agreement
valu
greater
report
idaho
technolog
inc
consist
find
rand
et
al
less
run
fail
despit
run
machin
almost
h
time
make
platform
robust
test
urgent
care
set
sever
failur
due
malfunct
one
machin
replac
without
failur
resolut
discrep
subset
mani
analyt
concord
dfa
result
major
unexpect
neg
resolv
true
neg
ldt
misinterpret
dfa
cleric
error
freezer
databas
mani
discrep
sampl
farp
detect
unexpect
posit
previous
detect
dfa
unexpect
posit
result
verifi
ldt
make
farp
favor
assay
analyt
except
adeno
three
unexpect
posit
analyt
detect
specimen
cohort
reflect
calcul
tabl
sinc
refer
method
analyt
dfa
neg
patient
test
specimen
neg
dfa
reflex
rvp
test
howev
rvp
detect
adeno
two
sampl
one
sampl
none
detect
farp
ldt
confirm
presenc
three
analyt
concentr
viru
specimen
close
calcul
lod
farp
like
explain
specimen
detect
nine
adeno
fals
neg
posit
dfaldt
n
rvpldt
n
suggest
farp
may
detect
serotyp
adeno
equal
sensit
sever
specimen
clearli
posit
culturedfa
measur
copiesml
ldt
though
concentr
sampl
fell
farp
lod
adeno
sever
sampl
within
rang
establish
lod
suggest
target
nucleic
acid
sequenc
amplifi
fact
farp
detect
adeno
subtyp
person
commun
idaho
technolog
inc
limit
share
rvp
howev
agreement
valu
adeno
consist
report
idaho
technolog
inc
analyt
troubl
current
perform
adopt
algorithm
includ
reflex
farp
neg
specimen
allow
comprehens
detect
pathogen
approach
would
appropri
laboratori
consid
farp
replac
dfa
altern
neg
specimen
could
submit
refer
laboratori
ldt
test
specif
adeno
though
longer
favor
scenario
two
unresolv
specimen
exclud
flub
cohort
due
lack
consensu
dfa
flub
ldt
flua
farp
neg
evid
mislabel
account
discrep
result
six
specimen
four
one
flub
one
flua
also
exclud
due
lack
specimen
repeat
culturefluoresc
antibodi
stain
pcr
discrep
result
initi
dfa
result
confirm
farp
thirteen
sampl
show
lack
concord
dfa
rvp
farp
final
resolut
tabl
two
specimen
dfa
cultur
posit
upon
reanalysi
one
specimen
determin
neg
dfa
ldt
one
flua
specimen
detect
dfa
ldt
one
unexpect
specimen
confirm
pool
individu
specimen
pool
test
ldt
singl
rhino
specimen
test
posit
rvp
ldt
neg
farp
five
farp
lod
within
approxim
log
ldt
tabl
remain
analyt
greater
log
less
sensit
correspond
ldt
adeno
rhino
bpert
lod
valu
log
higher
ldt
though
rel
differ
lod
strike
assay
abl
detect
posit
consist
cohort
clinic
specimen
except
adeno
interestingli
lod
valu
rsv
compar
low
ldt
farp
virus
lack
polymorph
target
nucleic
acid
consist
low
lod
farp
previous
shown
detect
rsv
sampl
rvp
could
detect
compar
lod
analysi
previous
perform
farp
inform
provid
adopt
laboratori
inform
rel
analyt
sensit
assay
measur
unit
univers
applic
molecular
diagnost
specimen
pool
prove
robust
applic
farp
evalu
purpos
run
capac
farp
approxim
one
pouch
per
min
therefor
signific
time
cost
invest
would
requir
individu
evalu
avail
analyt
use
robust
sampl
size
pool
analyt
order
achiev
high
number
posit
neg
specimen
well
test
overal
capabl
multiplex
platform
mix
infect
pool
shown
deleteri
effect
farp
abil
detect
target
analyt
well
pool
neg
impact
assay
lod
bpert
adeno
inher
limit
pool
clinic
specimen
evalu
purpos
failur
detect
target
analyt
may
mask
unexpect
posit
analyt
anoth
member
pool
instanc
pool
includ
flua
flub
rsv
rhino
hmpv
flub
may
undetect
intend
patient
posit
howev
anoth
patient
could
unexpect
flub
previous
undetect
may
detect
final
run
output
scenario
would
appreci
could
skew
agreement
statist
due
high
number
discrep
sampl
ran
multipl
pool
individu
singl
specimen
resolut
purpos
encount
hypothet
scenario
rhino
specimen
also
pcr
inhibitor
may
present
singl
specimen
may
dilut
pool
therefor
specimen
would
normal
miss
may
amplifi
though
scenario
document
comparison
studi
integr
specimen
includ
utmost
import
howev
even
pronounc
pool
specimen
though
prefer
util
patient
specimen
order
maintain
appropri
matrix
clinic
realist
analyt
concentr
commerci
manufactur
analyt
may
also
consid
pool
specimen
order
achiev
appropri
cohort
size
commerci
prepar
sampl
qualiti
control
result
littl
discrep
resolut
requir
laboratori
attract
attribut
laboratori
access
individu
ldt
well
rare
analyt
analyt
readili
avail
refer
method
valid
use
commerci
prepar
analyt
chose
use
primari
specimen
pediatr
popul
studi
simul
condit
assay
would
normal
oper
studi
also
serv
valid
farp
research
use
assay
preced
fda
approv
result
could
evalu
nine
fda
approv
analyt
includ
coronaviru
coronaviru
coronaviru
coronaviru
parainfluenza
influenza
subtyp
season
c
pneumonia
mycoplasma
pneumonia
also
confirm
specimen
bocaviru
approv
analyt
could
evalu
despit
identifi
pathogen
sever
pool
also
note
version
platform
provid
identif
rhinoviru
howev
fda
approv
product
report
analyt
rhinovirusenteroviru
farp
power
multiplex
pcr
platform
allow
moder
complex
laboratori
perform
molecular
respiratori
pathogen
detect
short
amount
time
assay
could
serv
valuabl
tool
clinic
decis
make
term
whether
admit
patient
respiratori
symptom
present
emerg
depart
importantli
report
serv
resourc
laboratori
interest
replac
dfa
favor
farp
demonstr
overal
perform
variou
analyt
primarili
clinic
specimen
well
provid
justif
pool
analyt
order
balanc
time
expens
robust
sampl
size
laboratori
consid
backup
method
adeno
detect
light
suboptim
perform
analyt
